BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MassBioEd Life Sciences Career Hub - ECPv6.17.5.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MassBioEd Life Sciences Career Hub
X-ORIGINAL-URL:https://careerhub.massbioed.org
X-WR-CALDESC:Events for MassBioEd Life Sciences Career Hub
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250424T090000
DTEND;TZID=America/New_York:20250424T160000
DTSTAMP:20250423T152855Z
CREATED:20250304T162536Z
LAST-MODIFIED:20250423T152855Z
UID:518-1745485200-1745510400@careerhub.massbioed.org
SUMMARY:Finance of Biotech – April 2025
DESCRIPTION:Course ID: C-3007\nThe deadline to apply for tuition reimbursement through the MA Express Program is April 2nd\, 2025.\nMembers of LabOps Unite\, please register here.\nMembers of Bio CT\, please register here.\n\n\nMember Rate: $925 \n\n\nNon-Member Rate: $1\,060 \n\n\nInterested in offering the training exclusively to a group of your employees? Email courses@massbioed.org to learn more. \nDescription\nThe Finance of Biotech focuses on various aspects of what’s needed for successful fundraising at each stage of company growth. The course addresses some of the common questions around risks of investing\, types of investment securities\, and differences between private and public markets. John Tagliamonte and Atul Deshpande\, CEO’s of biotech startups\, respectively\, will lead the course with invited guest lecturers from venture capital\, private equity\, investment banks\, and pharmaceutical companies. \n\nDate and Time\nThursday\, April 24th\, 2025\, 9:00 AM – 4:00 PM EST \nPlease plan to arrive at least 15 minutes before class starts. Class will start at 9:00 AM. We will have breaks in between. \nThis course will be held in-person. Breakfast and lunch will be provided at this all day workshop. \nTopics\n\nPrimary Risks of Biotech Investing\nStarting with Debt and/or Stock Equity\, Major Stages of Startup Financing\nDilutive and Non-Dilutive Funding\nAssessing Your Company’s Value\nCommon Types of Investment Securities\n\nInstructors\nJohn Tagliamonte\nChief Executive Officer\, Mellitus\n \n\n\nJohn Tagliamonte has more than 20 years of experience in executive leadership with responsibility for business development\, finance\, commercial and business operations\, strategic planning\, finance and legal functions with established and emerging public and private life sciences companies.  As the first Entrepreneur-in-Residence with MassBio\, he was responsible for forward-looking program content across the organization\, while helping to develop the next generation of biotech entrepreneurs. He currently serves on the business advisory boards of therapeutic startups WntRx\, Fractal\, MarkTx\, PhagePro and Tantu.  Previously he led business development at Juniper\, was Chief Business Officer of Oxyrane and held various executive business leadership roles at Anchor Therapeutics\, ImmunoGen and Johnson & Johnson\, as well as venture investing with Safeguard.  He began his career as a scientist at Dana-Farber Cancer Institute followed by global business unit management at Bio-Rad.  Mr. Tagliamonte received his M.B.A. from Boston College and his B.S. in molecular biology from Tufts University. \nAtul Deshpande\, Ph.D.\, MBA\nChief Executive Officer\, IMMEDIATE Therapeutics \nAtul is the CEO of IMMEDIATE Therapeutics\, a clinical stage biotech company dedicated to developing safe and effective therapeutic solutions to reduce heart muscle damage and prevent cardiac arrest in Acute Coronary Syndromes (ACS)\, the most common cause of death and morbidity across the world. \nBefore joining IMMEDIATE Therapeutics\, Atul was the Chief Strategy Officer and Head\, US Operations of Harbour BioMed (HBM). Atul was primarily responsible for building the company’s short- and long-term strategy and portfolio along with a robust execution plan. In addition\, he is also accountable for the HBM’s operations in both the US and EU to maintain HBM’s footprint across these 2 very important markets\, along with managing key alliances in these regions. In 2020\, he contributed to raising 2 VC funding rounds and taking the company public in the HK stock exchange raising a total of $400M. \nBefore HBM\, Atul served as the Global Operations Head for the Dupixent Franchise with Sanofi. He led the operations\, including marketing\, market access\, supply chain\, to launch Dupixent in 52 markets across the world for Atopic Dermatitis and in major markets for Asthma. Prior to this\, he led the operations for Sanofi’s Immunology R&D portfolio and was also responsible for new product planning and in-licensing evaluations. He spent 3 years in China as the Head of Asia Pacific R&D strategy to bring the global portfolio to China with minimal drug lag. Before Sanofi\, Atul worked as a management consultant for 9 years on projects across the value chain of pharma.  \nAtul holds a Ph.D. from UC Irvine in Neuroscience and a post-doc from UCLA.
URL:https://careerhub.massbioed.org/event/finance-of-biotech-april-2025/
LOCATION:MassBioEd Office (The Link)\, 255 Main Street\, Cambridge\, MA\, 02142\, United States
CATEGORIES:Industry Professionals
ATTACH;FMTTYPE=image/jpeg:https://careerhub.massbioed.org/wp-content/uploads/2025/03/green-header-2-7GvhOB.tmp_.jpg
END:VEVENT
END:VCALENDAR